Oral fish oil supplementation raises blood omega-3 levels and lowers C-reactive protein in haemodialysis patients--a pilot study
Saifullah A, Watkins BA, Saha C, Li Y, Moe SM, Friedman AN
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 90 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- National Institute of Diabetes and Digestive and Kidney Diseases
- Gobierno
- National Center for Research Resources
- Gobierno
- NCRR NIH HHS
- Gobierno
- NIDDK NIH HHS
- Subvenciones
- National Center for Research Resources (M01-RR 00750); National Institute of Diabetes and Digestive and Kidney Diseases (K24DK2775-7); National Center for Research Resources (K23 RR019615)
Según 4 financiadores declarados.
Publicación
- Publicado
- 2007-07-11 · Nephrol Dial Transplant · vol. 22 · número 12 · págs. 3561–3567
- Editorial
- Oxford University Press
- Citado
- 115 citas · más que el 94% de estudios similares · 4.6× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 21 trabajos
- Acceso
- De pago
- Áreas de investigación
- Fatty Acid Research and Health · Aquaculture Nutrition and Growth · Nutritional Studies and Diet
- Palabras clave
- fish oil supplementation, omega-3 fatty acids, eicosapentaenoic acid, docosahexaenoic acid, hemodialysis patients, C-reactive protein, omega-3 index, plasma fatty acids, cardiovascular risk markers, triglycerides, fish consumption, n-6/n-3 ratio
- MeSH
- humans, docosahexaenoic acids, eicosapentaenoic acid, fish oils, c-reactive protein, renal dialysis, pilot projects, double-blind method, dietary supplements, middle aged, female, male
6 autores
- Akber S. Saifullah🇺🇸Indiana University Bloomington; Indiana University Indianapolis; Indiana University School of Medicine
- Bruce A. Watkins🇺🇸Purdue University West Lafayette; Richard L. Roudebush VA Medical Center; Indiana University Bloomington; Indiana University Indianapolis; Indiana University School of Medicine; Indiana University – Purdue University Indianapolis
- Chandan Saha🇺🇸Purdue University West Lafayette; Richard L. Roudebush VA Medical Center; Indiana University Bloomington; Indiana University Indianapolis; Indiana University School of Medicine; Indiana University – Purdue University Indianapolis
- Y. Li🇺🇸Purdue University West Lafayette; Richard L. Roudebush VA Medical Center; Indiana University Bloomington; Indiana University Indianapolis; Indiana University School of Medicine; Indiana University – Purdue University Indianapolis
- Sharon M. Moe🇺🇸Purdue University West Lafayette; Richard L. Roudebush VA Medical Center; Indiana University Bloomington; Indiana University Indianapolis; Indiana University School of Medicine; Indiana University – Purdue University Indianapolis
- Allon N. Friedman🇺🇸Purdue University West Lafayette; Richard L. Roudebush VA Medical Center; Indiana University Bloomington; Indiana University Indianapolis; Indiana University School of Medicine; Indiana University – Purdue University Indianapolis
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
We previously reported that haemodialysis patients have suboptimal blood levels of the cardioprotective omega-3 polyunsaturated fatty acids (n-3 PUFA) eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids. In the present pilot study, we tested the hypothesis that supplementing haemodialysis patients for 12 weeks with the American Heart Association (AHA)-recommended fish oil dose would be well tolerated and efficacious in boosting blood n-3 PUFA levels and improving cardiovascular risk biomarkers.
Methods
Twenty-seven subjects were randomized in a 2 : 1 ratio to either 1.3 g of EPA + DHA daily or placebo.
Results
At baseline, 83% of subjects consumed inadequate dietary fish and had the following erythrocyte n-3 PUFA levels (mean +/- SD,% weight)-EPA: 0.3 +/- 0.2, DHA: 2.9 +/- 2.0, and ratio of n-6/n-3 PUFA: 4.2 +/- 1.3. Supplementation induced large increases in mean blood EPA and DHA levels (% increase, P-value vs placebo group): erythrocyte-EPA: +400%, P = 0.0018, DHA: +205%, P < 0.0001; plasma-EPA: +275%, P = 0.0003, DHA: +69%, P = 0.0352. Levels in the placebo group remained relatively unchanged. The omega-3 index, a value correlating with the level of cardioprotection, increased significantly in the fish oil group. A reduction in mean C-reactive protein levels (-3.3 +/- 8.1 mg/l, P = 0.0282) and a trend towards lower triglyceride levels (-24 +/- 74 mg/dl, P = 0.0783) were also observed in the active vs placebo group. Minimal side effects were noted.
Conclusions
Our preliminary observations that the AHA-recommended fish oil dose is well tolerated, efficacious and may improve surrogate markers of cardiovascular disease in haemodialysis patients paves the way for larger clinical trials to confirm a clinical benefit.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.